INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Veru Inc. (VERU) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) investors concerning the Company's possible violations of federal securities laws.
On November 9, 2022, the Pulmonary-Allergy Drugs Advisory Committee of the FDA voted against Veru's Emergency Use Authorization for its COVID-19 treatment, sabizabulin, explaining that there was "no direct evidence to support [sabizabulin's] antiviral activity."
On this news, Veru's stock price fell $8.04, or 53.6%, to close at $6.97 per share on November 10, 2022, thereby injuring investors.
If you purchased Veru securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...